Kinaxo | GenomeWeb

Kinaxo

This article originally ran on May 15 and has been updated to include additional comments from GlaxoSmithKline.
GlaxoSmithKline said today that it has entered an agreement to purchase chemical proteomics firm Cellzome for £61 million ($99 million).

By Adam Bonislawski
University of North Carolina researchers have developed a chemical proteomics approach to measure global kinase activity and used it to investigate drug resistance in triple-negative breast cancer.

The deal marks the first pharma alliance for Evotec since it acquired Kinaxo in mid-April in a deal worth up to $23 million.

Entitled "Proteome-wide quantification of small molecule binding to cellular target proteins," the patent encompasses the company's Cellular Target Profiling, KinAffinity, and Epigenetics Target Profiling services.

The agreement calls for Kinaxo to provide quantitative analyses of PTMs on a proteome-wide scale with the expectation that "such comprehensive analysis will gain valuable insights into cellular functions of potential drug targets," the company said in a statement.

In addition to biomarker discovery, Kinaxo's PhosphoScout technology will be used to assess the anti-cancer drug Nexavar's effects on cellular phosphorylation patterns.

Kinaxo Biotechnologies and Bayer Vital announced that they are collaborating to identify novel cancer treatment biomarkers.

New Products

Premium

Agilent Technologies, Bio-Rad, Bruker, Pressure BioScieces, Thermo Fisher Scientific, Pheonomenex, Kinaxo

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.